Actinogen ACW0002
Back to Drug Development Trials
![]()
Drug Development Trials
About the Actinogen ACW0002 trial
A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects with Mild Dementia due to Alzheimer’s Disease (AD)
Additional info:
For further information, please contact our team on Ph: 08 9389 6433 or Email: aarfctd@alzheimersresearch.org.au
